Hepatitis C-associated Osteosclerosis (HCAO): Long-Term Follow-Up of a New Case Recovered After Antiviral Treatment.
HCAO
HCV
Hepatitis C virus
Osteosclerosis
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
28
07
2023
accepted:
29
08
2023
medline:
2
11
2023
pubmed:
18
9
2023
entrez:
17
9
2023
Statut:
ppublish
Résumé
Hepatitis C-associated osteosclerosis (HCAO) is a very rare condition that can be observed in a small number of patients with Hepatitis C Virus (HCV) infection. HCAO is usually characterized by widespread bone sclerosis, associated with severe bone pain, and increased levels of bone turnover markers, especially alkaline phosphatase (ALP). In this report, we present the case of a 55-year-old woman who was affected by HCV and came to our attention for severe and diffuse bone pain. Radiological studies showed bone sclerosis, and bone mineral density (BMD) was markedly increased, as well as serum ALP levels. The patient was initially treated with intravenous pamidronate, which provided only a transient benefit on clinical symptoms. Then antiviral therapy for HCV (interferon-alfa and ribavirin) was started and it was effective in making the viral load undetectable. After a long follow-up period, we observed a persistent remission of bone pain, a reduction in BMD together with a progressive trend toward the normalization of bone turnover markers. In conclusion, HCAO, although rare, should be considered among the potential causes of increased bone mass in patients with HCV infection, and treatment for the underlying infection may be effective in controlling the manifestations of this disease.
Identifiants
pubmed: 37718324
doi: 10.1007/s00223-023-01135-7
pii: 10.1007/s00223-023-01135-7
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-577Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Whyte MP (2018) Sclerosing bone disorders. Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley, Hoboken, pp 823–838
doi: 10.1002/9781119266594.ch107
Villareal DT, Murphy WA, Teitelbaum SL et al (1992) Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med. https://doi.org/10.1016/0002-9343(92)90165-8
doi: 10.1016/0002-9343(92)90165-8
Diamond T, Depczynski B (1996) Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone. https://doi.org/10.1016/s8756-3282(96)00304-3
doi: 10.1016/s8756-3282(96)00304-3
Bergman D, Einhorn TI, Forster G (1996) Stone bone syndrome–diffuse sclerosis of bone: a newly described clinical disorder. EndocrPract. https://doi.org/10.4158/EP.2.4.296
doi: 10.4158/EP.2.4.296
Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res. https://doi.org/10.1002/jbmr.5650110417]
doi: 10.1002/jbmr.5650110417]
Whyte MP, Reasner CA (1997) Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med. https://doi.org/10.1016/s0002-9343(97)89507-1
doi: 10.1016/s0002-9343(97)89507-1
Hassoun AA, Nippoldt TB, Tiegs RD, Khosla S (1997) Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med. https://doi.org/10.1016/s0002-9343(97)00139-3]
doi: 10.1016/s0002-9343(97)00139-3]
Shaker JL, Reinus WR, Whyte MP (1998) Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J ClinEndocrinolMetab. https://doi.org/10.1210/jcem.83.1.4521]
doi: 10.1210/jcem.83.1.4521]
Wakitani S, Hattori T, Nakaya H et al (2003) Clinical images: hepatitis C–associated osteosclerosis. Arthritis Rheum. https://doi.org/10.1002/art.10770]
doi: 10.1002/art.10770]
Fiore CE, Riccobene S, Mangiafico R et al (2005) Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. OsteoporosInt. https://doi.org/10.1007/s00198-005-1858-8
doi: 10.1007/s00198-005-1858-8
Manganelli P, Giuliani N, Fietta P et al (2005) OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? ClinRheumatol. https://doi.org/10.1007/s10067-004-1031-3
doi: 10.1007/s10067-004-1031-3
Kaji H, Naito J, Sowa H et al (2006) Serum soluble factors induce the proliferation, alkaline phosphatase activity and transforming growth factor-beta signal in osteoblastic cells in the patient with hepatitis C-associated osteosclerosis. ExpClinEndocrinol Diabetes. https://doi.org/10.1055/s-2006-924399
doi: 10.1055/s-2006-924399
Tanaka T, Oki S, Muro S et al (2006) A case of hepatitis C-associated osteosclerosis in an elderly Japanese man. Endocr J. https://doi.org/10.1507/endocrj.k04-131
doi: 10.1507/endocrj.k04-131
Schwartz KM, Skinner JA (2008) Hepatitis C-associated osteosclerosis: a case report. Skeletal Radiol. https://doi.org/10.1007/s00256-008-0471-2
doi: 10.1007/s00256-008-0471-2
Shakado S, Akehi Y, Yotsumoto K et al (2011) A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin. Clin J Gastroenterol. https://doi.org/10.1007/s12328-011-0228-7
doi: 10.1007/s12328-011-0228-7
Javier R-M, Vernejoul M-C, Afif N et al (2011) Skeletal recovery from hepatitis C-associated osteosclerosis (HCAO) following antiviral treatment. Joint Bone Spine. https://doi.org/10.1016/j.jbspin.2011.02.016
doi: 10.1016/j.jbspin.2011.02.016
Hataya Y, Komatsu Y, Chusho H et al (2011) A case of hepatitis C-associated osteosclerosis with xanthogranulomatouscholecystitis. Intern Med. https://doi.org/10.2169/internalmedicine.50.4675
doi: 10.2169/internalmedicine.50.4675
Epperla N, McKiernan FE (2014) An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. Skeletal Radiol. https://doi.org/10.1007/s00256-014-1882-x
doi: 10.1007/s00256-014-1882-x
Serraino C, Melchio R, Silvestri A et al (2015) Hepatitis C-associated osteosclerosis: a new case with long-term follow-up and a review of the literature. Intern Med. https://doi.org/10.2169/internalmedicine.54.3448
doi: 10.2169/internalmedicine.54.3448
Miyamura N, Nishida S, Itasaka M et al (2016) A case of hepatitis C-associated osteosclerosis: accelerated bone turnover controlled by pulse steroid therapy. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/EDM-16-0097
doi: 10.1530/EDM-16-0097
pmcid: 5118973
de Camargo Vieira MC, Gonçalves WRB, Guerra RA et al (2021) Hepatitis C-associated osteosclerosis: improvement after treatment with sofosbuvir, daclatasvir, and ibandronate: case report and literature review. Calcif Tissue Int 109:104–109. https://doi.org/10.1007/s00223-021-00822-7
doi: 10.1007/s00223-021-00822-7
Beyer HS, Parfitt AM, Shih MS et al (1990) Case report: idiopathic acquired diffuse osteosclerosis in a young woman. J Bone Miner Res 5:1257–1263. https://doi.org/10.1002/jbmr.5650051211
doi: 10.1002/jbmr.5650051211
Beyer HS, Anderson Q, Shih MS et al (1993) Diffuse osteosclerosis in intravenous drug abusers. Am J Med 95:660–661. https://doi.org/10.1016/0002-9343(93)90364-U
doi: 10.1016/0002-9343(93)90364-U
Khosla S, Hassoun A, Baker B et al (1998) Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J ClinInvestig. https://doi.org/10.1172/jci1111
doi: 10.1172/jci1111
Khosla S, Ballard JF, Conover CA (2002) Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor I in patients with hepatitis-C associated osteosclerosis. J ClinEndocrinolMetab. https://doi.org/10.1210/jcem.87.8.8783
doi: 10.1210/jcem.87.8.8783
Radkowski M, Kubicka J, Kisiel E et al (2000) Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 95:3986–3989. https://doi.org/10.1182/blood.V95.12.3986
doi: 10.1182/blood.V95.12.3986
Pawlotsky J-M, Negro F, Aghemo A et al (2020) EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol 73:1170–1218. https://doi.org/10.1016/j.jhep.2020.08.018
doi: 10.1016/j.jhep.2020.08.018